HighTower Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-212,260
| Closed | -$266K | – | 3678 |
|
|
2022
Q1 | $266K | Hold |
212,260
| – | – | ﹤0.01% | 2618 |
|
|
2021
Q4 | $246K | Hold |
212,260
| – | – | ﹤0.01% | 2613 |
|
|
2021
Q3 | $408K | Sell |
212,260
-10
| -0% | -$20 | ﹤0.01% | 2205 |
|
|
2021
Q2 | $496K | Buy |
212,270
+2,210
| +1% | +$5.33K | ﹤0.01% | 2055 |
|
|
2021
Q1 | $569K | Hold |
210,060
| – | – | ﹤0.01% | 1898 |
|
|
2020
Q4 | $508K | Hold |
210,060
| – | – | ﹤0.01% | 1636 |
|
|
2020
Q3 | $481K | Buy |
210,060
+41,575
| +25% | +$109K | ﹤0.01% | 1592 |
|
|
2020
Q2 | $387K | Buy |
168,485
+1,250
| +0.7% | +$2.88K | ﹤0.01% | 1587 |
|
|
2020
Q1 | $287K | Buy |
167,235
+3,000
| +2% | +$6.06K | ﹤0.01% | 1599 |
|
|
2019
Q4 | $339K | Buy |
164,235
+1,000
| +0.6% | +$2.37K | ﹤0.01% | 1642 |
|
|
2019
Q3 | $474K | Sell |
163,235
-6,500
| -4% | -$22.2K | ﹤0.01% | 1543 |
|
|
2019
Q2 | $666K | Buy |
169,735
+126,347
| +291% | +$659K | ﹤0.01% | 1382 |
|
|
2019
Q1 | $206K | Buy |
43,388
+28,750
| +196% | +$142K | ﹤0.01% | 1946 |
|
|
2018
Q4 | $34K | Buy |
14,638
+4,375
| +43% | +$21.8K | ﹤0.01% | 2055 |
|
|
2018
Q3 | $64K | Buy |
10,263
+4,000
| +64% | +$21.1K | ﹤0.01% | 2103 |
|
|
2018
Q2 | $43K | Buy |
6,263
+2,513
| +67% | +$18.8K | ﹤0.01% | 2073 |
|
|
2018
Q1 | $32K | Buy |
+3,750
| New | +$31.1K | ﹤0.01% | 2045 |
|
Other funds holding GNCA
HighTower Advisors's GNCA Position: Q2 2022 in Review
HighTower Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 212,260 shares — an estimated $266K sold.
HighTower Advisors first reported a position in GNCA in Q1 2018 and held it in 17 quarters. The position peaked at $666K in Q2 2019. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- HighTower Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- HighTower Advisors sold 212,260 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $266K.
- HighTower Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 17 quarters.
- HighTower Advisors's Genocea Biosciences, Inc. position peaked at $666K in Q2 2019.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.